Archive: 04/06/2018
Drug combination slows growth of most common type of advanced breast cancer
The combination of taselisib and fulvestrant has shown to slow the growth of cancer in post-menopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor-2 (HER2) negative, PIK3CA-mutant, inoperable, ...
Jun 4, 2018